Change of COO at Idorsia

30 May 2023

Swiss biotech Idorsia (SIX: IDIA) today revealed that Simon Jose will leave his position as chief commercial officer and member of the Idorsia executive committee to pursue other opportunities.

As a result, Idorsia says that Otto Schwarz has agreed to advise the management team on commercial operations effective July 1, 2023.

Mr Schwartz is a highly accomplished industry executive with more than 35 years of experience. He has launched multiple major specialty products on a global basis. Most recently, he served as executive vice president, chief operating officer and a member of the Actelion executive committee, until the acquisition of Actelion by Johnson & Johnson (NYSE: JNJ), which also resulted in the spin-out of Idorsia in 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK